This information is intended for healthcare professionals based in Ireland.

ELIQUIS® for venous thromboembolic events (VTE) prevention in orthopaedic surgery

In the absence of prophylaxis, the incidence of DVT is approximately 40%–60% following major lower limb orthopaedic surgery, and fatal PE can occur in up to one patient per 300 total hip replacements.1

ELIQUIS® is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.2

For full information on therapeutic indications, please visit SmPC.

Learn more about

Risk Minimisation Materials

The Eliquis (apixaban) Prescriber Guide and Patient Alert Card are risk minimisation materials developed for all indications as an aid to prescribing, in particular they are aimed at increasing awareness about the potential risk of bleeding during treatment with apixaban and providing guidance on how to manage that risk. Printed copies of these educational materials may be obtained by contacting the Bristol-Myers Squibb Medical Information Department (telephone: 1800 749 749; e-mail: Alternatively, electronic copies can be accessed via the HPRA website at


  1. Geerts WH, Bergqvist D, Pinso GF. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:381S-453S.
  2. ELIQUIS® (apixaban) Summary of Product Characteristics.